...

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY

To study a new anti-obesity medication

Why this Research Matters

To study effectiveness, safety and tolerability of a new investigational medication (PF-07976016) in adults with obesity

Who can Participate

Adult

18-74 years old; BMI of 30 or greater; Do not have type 1 or type 2 diabetes; Have not taken any weight loss medications in last 12 weeks

Study ID

Protocol Number: 24-2153

Meet the Team

Image of Principal Investigator

Daniel Bessesen, MD

Principal Investigator

Categories

Locations

  • Anschutz Health and Wellness
  • Outpatient CTRC